SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Peer Review reports

Original Submission
22 Jan 2021	Submitted	Original manuscript
13 Jul 2021	Reviewed	Reviewer Report - Kirsty Loudon
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
15 Jul 2021	Editorially accepted
19 Aug 2021	Article published	10.1186/s13063-021-05461-9

Back to article page